tbuckley/cabot-search huggingface dataset:
Comparison of hepatic artery embolization and selective internal radiation therapy for metastatic neuroendocrine tumors.
Authors: Eric Steven Engelman, Roberto Leon-Ferre, Boris Naraev, Nancy Sharma, Shiliang Sun, Thomas M. O'Dorisio, Thorvardur Ragnar Halfdanarson
Journal: Journal of Clinical Oncology (2012)

332 Background: Liver-directed therapies can be beneficial in reducing morbidity and mortality in patients with metastatic neuroendocrine tumors (mNETs). We compared the clinical outcomes of patients treated with hepatic artery embolization/chemoembolization (HA(C)E) or selective internal radiation therapy (SIRT) with SIR-Spheres at our institution over the last ten years. Methods: Medical records of 42 mNET patients with hepatic metastases treated with either bland hepatic artery embolization (HAE), chemoembolization (HACE), or SIRT at the University of Iowa from 2001 to 2011 were analyzed. Chi-square and Wilcoxon rank-sum tests were performed to compare the groups. Time to progression (TTP) and overall survival (OS) were calculated using Kaplain-Meier analysis. Results: The tumors were located in the small bowel in 21 patients (50%), pancreas in 8 (19%), lung in 2 (5%), and other locations in 11 patients (26%). Ten patients (24%) had extra-hepatic metastases. 13 patients had HAE, 17 patients had HACE and 12 patients had SIRT. 20 of these patients had a second procedure with 6 receiving SIRT, 9 HAE and 5 HACE. TTP was similar between SIRT (15.1 months) and HAE or HACE (19.6 months) (p= 0.968). There was a trend towards an increased TTP in patients receiving HACE (33.4 months), compared to HAE (12.1 months) or SIRT (15.1 months) (p = 0.512). The overall survival for all patients from the first intervention was 41.9 months. Conclusions: There appears to be no significant difference in TTP in patients treated with SIRT compared to patients treated with HAE or HACE in this cohort; however, there may be a trend towards a longer time to disease progression in patients treated with chemoembolization compared to the other two modalities. Patients tend to have a prolonged survival after all three liver-directed therapies.
<i>Notes from the Field</i>: Investigation of <i>Elizabethkingia anophelis</i> Cluster — Illinois, 2014–2016
Authors: Livia Navon, Whitney J. Clegg, Jodi Morgan, Connie Austin, John R. McQuiston, David D. Blaney, Maroya Spalding Walters, Heather Moulton-Meissner, Ainsley Nicholson
Journal: MMWR Morbidity and Mortality Weekly Report (2016)
Peripheral T-Cell Lymphoma-Unspecified (PTCL-U) and NK/T-Cell Lymphoma Showed a Significantly Poor Prognosis in a Randomized Controlled Trial (RCT) JCOG9002 with Multidrug Combination Chemotherapy for Aggressive Lymphoma.
Authors: Tomohiro Kinoshita, Tomomitsu Hotta, Taro Shibata, Kiyoshi Mukai, Motoko Yamaguchi, Kunihiro Tsukasaki, Yoshitoyo Kagami, Masaharu Kasai, Kensei Tobinai, Masanori Shimoyama
Journal: Blood (2006)
Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.
Authors: Shaji Kumar, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, S. Vincent Rajkumar, Thomas E. Witzig, John A. Lust, Philip R. Greipp, Robert Kyle, Mark R. Litzow, Morie A. Gertz
Journal: Blood (2004)
Utilizing metformin as a radiosensitizing agent in the treatment of prostate cancer.
Authors: L. Klotz, N. Venier, A. Vandersluis, R. Besla, N. Fleshner, M. N. Pollak, V. Venkateswaran, A. J. Colquhoun
Journal: Journal of Clinical Oncology (2011)

89 Background: External beam radiation therapy (EBRT) is a well recognized curative prostate cancer (PCa) treatment modality utilizing ionizing radiation (IR). In addition to mediating DNA damage, IR upregulates several intracellular pro-survival pathways including the insulin- like growth factor (IGR) signaling network. This may contribute to the intrinsic radioresistance exhibited by certain tumors. Diabetic patients with PCa experience poorer outcomes following EBRT than their non-diabetic counterparts. Some attribute this to diabetes-induced chronic hyperinsulinemia with consequent upregulation of pro-survival insulin/IGF signalling. Previous work by our group showed diet-induced hyperinsulinemia to enhance PCa tumor growth in vivo. Metformin, a diabetic treatment, alleviates hyperinsulinemia, and also exhibits anti-neoplastic properties. We postulate that pre-treatment with metformin to correct hyperinsulinemia may protect cells from radiation-mediated pro-survival insulin/IGF signaling. Thus we assessed the radiosensitizing potential of metformin using in vitro and in vivo PCa models. Methods: The effect of IR and/or metformin on colony formation rates was assessed in LNCaP, PC3, DU145 and PC3AR2 PCa cell lines using clonogenic assay. The combination treatment regimen was assessed in vivo using a murine xenograft model. Western blot and cell cycle analyses are ongoing to try and elucidate any mechanisms of interaction between metformin and IR. Results: Monotherapy with IR (1-8Gy) or metformin (0.01-10.0mM) caused significant dose-dependent reduction in colony formation rates (p&lt;0.001). Combination treatment further significantly reduced colony formation rates (p&lt;0.03). Preliminary results from our in vivo study show diminished tumor growth in response to combination treatment (p&lt;0.0001), and are currently subject to ongoing statistical analyses. Conclusions: Our in vitro findings confirm combining metformin with IR significantly reduces PCa cell colony formation rates further than either monotherapy. Recapitulation of these results in vivo would provide justification for translating this work into a phase II clinical trial of metformin as a radiosensitizing agent. No significant financial relationships to disclose.
Myeloablative Conditioning with Pharmacokinetic-Targeted Intravenous Busulfan and Cyclophosphamide in Unrelated Cord Blood Transplantation for Myeloid Malignancies in Children
Authors: Henrique Bittencourt, Marc Ansari, Mohamed Aziz Rezgui, Samira Meziani, Marie-France Vachon, Catherine Desjean, Michel Duval, Yves Théoret, Maja Krajinovic
Journal: Blood (2011)
Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Update of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324).
Authors: Luca Baldini, Alessandro Pulsoni, Giuseppe Rossi, Umberto Vitolo, Enrica Morra, Barbara Olivero, Elena Cavalieri, Francesco Merli, Luigi Rigacci, Francesco Nobile, Andrea Ferrario, Lorella Orsucci, Maura Brugiatelli, Pellegrino Musto, Giorgio Lambertenghi Deliliers, Enrica Gamba
Journal: Blood (2009)
Outbreak of enterovirus D68 of the new B3 lineage in Stockholm, Sweden, August to September 2016
Authors: Robert Dyrdak, Malin Grabbe, Berit Hammas, Jonas Ekwall, Karin E Hansson, Joachim Luthander, Pontus Naucler, Henrik Reinius, Maria Rotzén-Östlund, Jan Albert
Journal: Eurosurveillance (2016)

We report an enterovirus D68 (EV-D68) outbreak in Stockholm Sweden in 2016. Between 22 August and 25 September EV-D68 was detected in 74/495 respiratory samples analysed at the Karolinska University Hospital. During the peak week, 30/91 (33%) samples were EV-D68 positive. Viral protein (VP)P4/VP2 sequencing revealed that cases were caused by B3 lineage strains. Forty-four (59%) EV-D68-positive patients were children aged ≤ 5 years. Ten patients had severe respiratory or neurological symptoms and one died.
Akermanite used as an alkaline biodegradable implants for the treatment of osteoporotic bone defect
Authors: Wenlong Liu, Ting Wang, Xiaoli Zhao, Xiuli Dan, William W. Lu, Haobo Pan
Journal: Bioactive Materials (2016)

In osteoporosis scenario, tissue response to implants is greatly impaired by the deteriorated bone regeneration microenvironment. In the present study, a Mg-containing akermanite (Ak) ceramic was employed for the treatment of osteoporotic bone defect, based on the hypothesis that both beneficial ions (e.g. Mg2+ect.) released by the implants and the weak alkaline microenvironment pH (μe-pH) it created may play distinct roles in recovering the abnormal bone regeneration by stimulating osteoblastic anabolic effects. The performance of Ak, β-tricalcium phosphate (β-TCP) and Hardystone (Har) in healing a 3 mm bone defect on the ovariectomized (OVX) osteoporotic rat model was evaluated. Our results indicated that, there's more new bone formed in Ak group than in β-TCP or Har group at week 9. The initial μe-pHs of Ak were significantly higher than that of the β-TCP and Blank group, and this weak alkaline condition was maintained till at least 9 weeks post-surgery. Increased osteoblastic activity which was indicated by higher osteoid secretion was observed in Ak group at week 4 to week 9. An intermediate layer which was rich in phosphorus minerals and bound directly to the new forming bone was developed on the surface of Ak. In a summary, our study demonstrates that Ak exhibits a superior bone regenerative performance under osteoporosis condition, and might be a promising candidate for the treatment of osteoporotic bone defect and fracture.
Heavy objects and small children: Developmental data extend the passive frame theory
Authors: Cheshire Hardcastle, Eliah White, Heidi Kloos, Valerie Gray Hardcastle
Journal: Behavioral and Brain Sciences (2016)

Abstract Passive frame theory is compatible with modern complexity theory and the idea that conflict drives the emergence of a novel structural organization. After describing new developmental data, we suggest that this conflict needs to be expanded to include not only conflict between action options, but also between action and perception.
Radiosurgery Plus Whole-Brain Radiation Therapy for Brain Metastases—Reply
Authors: Jeffrey Raizer
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels
Authors: Jakub Tolar, H. Joachim Deeg, Sally Arai, Mitchell Horwitz, Joseph H. Antin, John M. McCarty, Roberta H. Adams, Mary Eapen, Marian Ewell, Eric Leifer, Iris Gersten, Shelly L Carter, Mary M. Horowitz, Dennis L Confer, Ryotaro Nakamura, Michael Pulsipher, Nancy L DiFronzo, Paolo Anderlini
Journal: Blood (2011)
Redirected CD4+ T Cells Using WT1-Specific T-Cell Receptor Gene Transfer Can Supply Multifactorial Help to Enhance the Anti-Leukemia Reactivity Mediated by Similarly Redirected CD8+ T Cells Using the Identical Gene Transfer
Authors: Toshiki Ochi, Hiroshi Fujiwara, Sachiko Okamoto, Hiroaki Asai, Yukihiro Miyazaki, Toshiaki Shirakata, Junichi Mineno, Kiyotaka Kuzushima, Hiroshi Shiku, Masaki Yasukawa
Journal: Blood (2011)
TITAN: Ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): Preliminary toxicity of a Sarah Cannon Research Institute phase III trial.
Authors: D. A. Yardley, J. D. Hainsworth, W. N. Harwin, S. A. Goble, B. R. Daniel, M. A. Ackerman, D. Shipley, D. R. Drosick, S. E. Hanson, P. L. Griner, H. A. Burris
Journal: Journal of Clinical Oncology (2011)

1103 Background: Ixabepilone (Ixa) is a potent tubulin polymerizer active in taxane refractory and locally advanced breast cancer as well as in TNBC. The clinical activity and toxicity profile of Ixa are similar to the taxanes with neuropathy and myelosuppression as dose-limiting toxicities. We present the preliminary toxicity of Ixa compared to weekly paclitaxel (Pac) following AC x 4, performed as part of the data safety monitoring in this trial. Methods: Eligibility criteria: TNBC (defined as ER and PR <10% by IHC and HER2 IHC 0-1+ or FISH negative), node positive or node negative with any tumor size, post surgery with no evidence metastatic disease. Patients (pts) were randomized to AC (60/600mg/m2) q3wks x4 followed by Ixa (40mg/m2 q 3wks x4) or weekly Pac (80mg/m2 x12 weeks). Growth factor support was permitted. Analysis is based on the first 226 women completing therapy (AC/Ixa, 120; AC/Pac, 106). Results: Median pt age was 54 years; 36% lymph node positive; 50% T2; 88% ductal histology. 10 pts (8%) did not complete AC/Ixa due to toxicity (hematologic – 2; nonhematologic – 8) versus 18 (17%) with AC/Pac (hematologic – 3; nonhematologic – 15). Neuropathy was the most common cause of treatment discontinuation in both arms, occurring more frequently in Pac pts (10 pts vs. 3 Ixa pts). Other discontinuation events were similar between the arms and included hypersensitivity, fatigue, rash, and pain. Toxicities were reported in their expected frequencies during AC, including 6 pts with G3 febrile neutropenia. Grade 3/4 toxicity during Pac and Ixa portions of treatment is summarized in the table. Conclusions: As part of adjuvant chemotherapy, Ixa is feasible with a toxicity profile similar to weekly Pac. Neuropathy was the most frequent cause of study discontinuation, and occurred more frequently in pts receiving Pac. Grade 3/4 toxicity Paclitaxel N = 106 Ixabepilone N=120 Hematologic Anemia 9 (8%) 16 (13%) Neutropenia 5 (5%) 10 (8%) Thrombocytopenia 0 3 (3%) Febrile neutropenia 1 (<1%) 0 Nonhematologic Neuropathy – peripheral 8 (8%) 6 (5%) Fatigue 8 (8%) 5 (4%) Diarrhea 2 (2%) 2 (2%) Arthralgia 1 (<1%) 3 (3%)
Change of serum vitamin D according to the breast cancer treatment.
Authors: H. J. Kim, S. Ahn
Journal: Journal of Clinical Oncology (2011)

172 Background: Vitamin D deficiency is associated with increased breast cancer risk and decreased breast cancer survival. The purpose of this study was to determine the effect of breast cancer adjuvant treatment to the vitamin D status, as measured by the serum hydroxyvitamin D (25OHD) in breast cancer patients. Methods: For 589 patients who was diagnosed as a non metastatic breast cancer in 2009 at the asan medical center, blood was prospectively analyzed in batches for serum 25 OHD level at basal and at 6 and 12month. We excluded the patients who took a vitamin D supplementation and got a neoadjuvant chemotherapy. Vitamin D sufficiency was defined as serum as 30ng/ml or greater, insufficiency as 20 to 29 ng/ml and insufficiency as less than 20ng/ml. Results: At baseline, mean serum 25OHD was greater in summer (April to Oct) than Winter (Nov to May ) (28.2ng/ml vs 32.9ng/ml respectively, p=0.000). The patients who did not get a chemotherapy and anti-hormonal therapy as baseline, the patient with chemotherapy showed decreased serum 25OHD level than who without chemotherapy in 6 month but not in 12 month (p=0.003, vs p=0.156 respectively). The patients who had taken anti-hormonal therapy showed significant increasing serum 25OHD in 6 month and 12 months (p=0.000 both). For the patients who got both chemotherapy and anti-hormonal therapy, the changes of serum 25OHD level is smaller than the patients who got a chemotherapy only. For the patients who got a chemotherapy, 57% of patients were vitamin D sufficient at baseline, but 27% of patients in 6 month and 49% in 12 month (p=0.001). Conclusions: Vitamin D status was worse during chemotherapy but recovered after chemotherapy. Antihormonal therapy make the serum vitamin D level increased. The translational research about the effect of chemotherapy and antihormonal therapy to the vitamin D status should be warranted.
American Heart Association Newly Elected Fellows, Spring 2008
Journal: Circulation Research (2008)

Fifty Premium Professional Members were elected Fellows and International Fellows of the American Heart Association (AHA) in spring 2008. Fellows are elected on the basis of their outstanding credentials, achievements, and community contributions to cardiovascular disease and stroke. Persons elected to fellowship are entitled to use FAHA, Fellow of the American Heart Association, as a professional designation. Fellows who reside outside the United States and Canada are designated International Fellows. For more information on the AHA Fellowship program, please visit our Web site at http://www.americanheart.org/presenter.jhtml?identifier=3033104

S. Helena Kuivaniemi, MD, PhD, FAHA 

Wayne State University School of Medicine

Detroit, Mich

Rene J. Alvarez, Jr, MD, FAHA 

University of Pittsburgh Medical Center

Wexford, Pa

Mark A. Fogel, MD, FAHA 

University of Pennsylvania School of Medicine

Philadelphia, Pa

Joel T. Hardin, MD, FAHA 

UMDNJ-New Jersey …
Diffuse Esophageal Spasm: Clinical, Radiologic, and Manometric Observations.
Authors: Harold P. Roth
Journal: Annals of Internal Medicine (1964)

s1 February 1964Diffuse Esophageal Spasm: Clinical, Radiologic, and Manometric Observations.Harold P. Roth, M.D., F.A.C.P., Bertram Fleshier, M.D.Harold P. Roth, M.D., F.A.C.P.Search for more papers by this author, Bertram Fleshier, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-60-2-325_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptCurling, also called tertiary waves and corkscrew esophagus, is often dismissed as an insignificant X-ray finding. Symptoms may be associated with a similar X-ray appearance; the syndrome is then called diffuse esophageal spasm. Ten patients with this syndrome symptomatic were studied in the past 3 years. They had attacks of dysphagia, substernal pain, and in one case, syncope. Symptoms appeared before age 35 in two patients and before 50 in three others. The radiologic manifestations did not parallel the clinical severity. No abnormality was noted on the initial routine X-ray examination of four patients. However, a typical X-ray pattern was... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Harold P. Roth, M.D., F.A.C.P.; Bertram Fleshier, M.D.Affiliations: Cleveland, Ohio PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1964Volume 60, Issue 2_Part_1Page: 325-325KeywordsDysphagiaEsophagusSyncope ePublished: 1 December 2008 Issue Published: 1 February 1964 PDF downloadLoading ...
Use of cellular context to determine sarcoma phenotype in a new mouse sarcoma model.
Authors: S. Hettmer, J. Liu, C. M. Miller, R. T. Bronson, D. M. Langenau, A. J. Wagers
Journal: Journal of Clinical Oncology (2011)

10029 Background: Soft-tissue sarcomas are heterogeneous malignancies of mesodermal, non-hematopoietic origin. They may present with tissue-specific differentiation, such as myogenic features in rhabdomyosarcoma. However, the cellular origins of sarcomas in skeletal muscle have remained controversial. Methods: This study sought to investigate the effects of cell context on the outcome of sarcoma-associated genetic lesions by ex-vivo genetic perturbation and orthotopic implantation of muscle satellite cells (sorted as CD45-MAC1-TER119-Sca1-β1-integrin+CXCR4+ cells) and non-myogenic precursors (sorted as CD45-MAC1-TER119-Sca1+ cells), freshly isolated by fluorescence-activated cell sorting from p16p19nullmouse skeletal muscle, infected with Kras(G12V)-pGIPZ-IRES-GFP lentivirus, and injected into the gastrocnemius muscles of immunocompromised NOD.SCID mice. Results: We show that mouse Kras-expressing; p16p19null muscle satellite cells can serve as cells-of-origin for mouse rhabdomyosarcomas (MyoD, Myogenin and Desmin positive) with non-alveolar, pleomorphic features. Conversely, Kras-expressing; p16p19null non-myogenic progenitors typically induce non-myogenic, pleomorphic sarcomas (MyoD, Myogenin and Desmin negative). Despite initiation in distinct cells-of-origin, Kras; p16p19null sarcomas share a common, Ras-predominated transcriptional signature that is enriched in human soft-tissue sarcomas and suggests that Ras-pathway activation is an important event in human sarcomas. Moreover, our bioinformatic analyses identify a small group of genes that are upregulated in sarcomas across species and may hold broad therapeutic relevance. Conclusions: In summary, we have established a highly tractable chimeric mouse model for the induction of sarcomas in skeletal muscle, which demonstrates that the lineage commitment of the target cell into which oncogenetic hits are introduced is critical in determining sarcoma phenotype. This new sarcoma model recapitulates genetic events in human soft-tissue sarcomas, can be used as a platform to dissect the cellular and genetic events responsible for sarcoma development and may accelerate future therapeutic discovery efforts in the sarcoma field.
CpG-island methylation of GATA-family members <i>GATA3</i> and <i>GATA5</i> in renal cell carcinoma and association with clinicopathological parameters and progression-free survival.
Authors: Inga Peters, Kai Gebauer, Faranaz Atschekzei, Joerg Hennenlotter, Mario W. Kramer, Wolfgang Traenkenschuh, Axel S. Merseburger, Markus Kuczyk, Juergen Serth
Journal: Journal of Clinical Oncology (2012)

370 Background: Transcriptional inactivation and CGI methylation of GATA3 and −5 has been reported to be involved in mammary carcinoma, pancreatic cancer, colorectal and gastric carcinogenesis. A recent study demonstrated that a loss of GATA-3 expression due to partially methylation silencing in several renal cell carcinoma (RCC) patients. We quantitatively investigated GATA3 and −5 CGI methylation in RCC and analyzed its association with clinical characteristics as well as progression free survival of patients. Methods: Methylation data were obtained from a quantitative methylation-specific polymerase chain reaction assay (QMSP) for both genes. We investigated 108 RCC and 77 paired tissue samples as well as six RCC cell lines. Statistical analyses were carried out using the paired t-test for matched tumor (TU) and adjacent normal (adN) samples, logistic regression for comparisons of independent samples and cox regression for survival analysis. Results: In paired samples we found a significant higher methylation in TU compared to adN for GATA3 (P=0.007) and for GATA5 (P=3.6*10 −9 ) for all RCCs. GATA5 showed also strong correlations between methylation and status of metastasis (P=0.05) and advanced (pT≥3 and/or N+, M+) tumor samples compared to localized (pT≤2, N0, M0) tumors (P=4.7*10 −9 ). A decreased progression free survival in cox proportional hazard model analysis could be demonstrated for patients with a high GATA5 methylation (P=0.0006, HR=6.5) and a trend could also be seen for GATA3 methylated patients (P=0.06). Conclusions: GATA3 and −5 were identified to demonstrate tumor-specific CGI hypermethylation in renal cell cancer patients. The association of GATA5 CGI methylation with metastasis, advanced disease and progression free survival of patients indicates that epigenetic alterations of both genes are involved in renal cell carcinogenesis. GATA5 methylation could serve as a biomarker for tumor progression. Further prospective and functional investigations are necessary to clarify whether CGI methylation of GATA family members can provide independent information for future clinical management of patients with RCC.